Goldman Sachs
PBE icon

Goldman Sachs’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Goldman Sachs’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Buy
4,021
+414
+11% +$33.5K ﹤0.01% 5865
2025
Q4 		$296K Sell
3,607
-93
-3% -$7.2K ﹤0.01% 5870
2025
Q3 		$259K Sell
3,700
-39,488
-91% -$2.67M ﹤0.01% 5838
2025
Q2 		$2.77M Buy
43,188
+5,531
+15% +$343K ﹤0.01% 3920
2025
Q1 		$2.39M Buy
37,657
+2,103
+6% +$142K ﹤0.01% 4002
2024
Q4 		$2.37M Buy
35,554
+29,709
+508% +$2.05M ﹤0.01% 4140
2024
Q3 		$408K Buy
+5,845
New +$405K ﹤0.01% 5164
2023
Q3 		– Sell
-5,454
Closed -$334K – 5776
2023
Q2 		$334K Sell
5,454
-2,067
-27% -$129K ﹤0.01% 4961
2023
Q1 		$472K Buy
7,521
+99
+1% +$6.38K ﹤0.01% 4849
2022
Q4 		$471K Buy
+7,422
New +$471K ﹤0.01% 4899
2022
Q1 		– Sell
-6,361
Closed -$453K – 6827
2021
Q4 		$453K Sell
6,361
-7,063
-53% -$511K ﹤0.01% 5446
2021
Q3 		$1M Buy
+13,424
New +$1.02M ﹤0.01% 4733
2017
Q4 		– Sell
-5,120
Closed -$256K – 6566
2017
Q3 		$256K Sell
5,120
-1,384
-21% -$65.6K ﹤0.01% 5589
2017
Q2 		$297K Sell
6,504
-5,832
-47% -$252K ﹤0.01% 5520
2017
Q1 		$522K Sell
12,336
-53,905
-81% -$2.26M ﹤0.01% 4992
2016
Q4 		$2.57M Buy
66,241
+5
+0% +$202 ﹤0.01% 3614
2016
Q3 		$2.78M Sell
66,236
-582
-0.9% -$23.9K ﹤0.01% 3544
2016
Q2 		$2.47M Buy
66,818
+47
+0.1% +$1.84K ﹤0.01% 3429
2016
Q1 		$2.56M Buy
66,771
+479
+0.7% +$18.6K ﹤0.01% 3262
2015
Q4 		$3.35M Sell
66,292
-367
-0.6% -$18.1K ﹤0.01% 3187
2015
Q3 		$3.05M Sell
66,659
-1,334
-2% -$74.6K ﹤0.01% 3356
2015
Q2 		$3.97M Sell
67,993
-1,569
-2% -$89.7K ﹤0.01% 3170
2015
Q1 		$3.84M Buy
69,562
+5,326
+8% +$288K ﹤0.01% 3151
2014
Q4 		$3.23M Sell
64,236
-1,216
-2% -$59.5K ﹤0.01% 3390
2014
Q3 		$3.02M Sell
65,452
-26,160
-29% -$1.18M ﹤0.01% 3517
2014
Q2 		$4M Buy
91,612
+70,903
+342% +$2.87M ﹤0.01% 3276
2014
Q1 		$862K Buy
20,709
+10,411
+101% +$445K ﹤0.01% 4824
2013
Q4 		$382K Buy
+10,298
New +$369K ﹤0.01% 5511

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Goldman Sachs's PBE Position: Q1 2026 in Review

Goldman Sachs increased its Invesco Biotechnology & Genome ETF (PBE) stake by 11% in Q1 2026, buying an estimated $33.5K and bringing the position to 4,021 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #5865.

Goldman Sachs first reported a position in PBE in Q4 2013 and has held it in 28 quarters since. The position peaked at $4M in Q2 2014. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Goldman Sachs held 4,021 shares of Invesco Biotechnology & Genome ETF worth $318K as of Q1 2026.
  • Goldman Sachs bought 414 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $33.5K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5865 holding.
  • Goldman Sachs first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and has held it in 28 quarters since.
  • Goldman Sachs's Invesco Biotechnology & Genome ETF position peaked at $4M in Q2 2014.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.